This report describes the global market size of Non-Human Primate Pre-clinical studies at Contract Market from 2019 to 2022 and its CAGR from 2019 to 2023, and also forecasts its market size to the end of 2031 and is expected to grow with a CAGR of 18.5%% from 2024 to 2031.
Due to the COVID-19 pandemic, the global market for Non-Human Primate Pre-clinical studies at Contract Market estimated at US 29.8 $ billion in the year 2023, is projected to reach a revised size of US 52.6$ million by 2031, growing at a CAGR of 18.5% during the forecast period 2024-2031.
Non-Human Primate (NHP) pre-clinical studies at Contract Research Organizations (CROs) involve testing potential therapies or medical devices on non-human primates before human clinical trials. These studies assess the safety, efficacy, pharmacokinetics, and toxicology of the product, providing critical data to ensure human trial safety. NHPs, due to their genetic and physiological similarities to humans, are often used for complex disease models. CROs conduct these studies under stringent ethical and regulatory standards to minimize animal use and ensure welfare compliance. This phase is crucial in drug development, especially for vaccines, biologics, and neurological treatments.
For geography segment, regional supply, demand, major players, price is presented from 2019 to 2031. This report cover following regions:
North America
Asia-Pacific
Europe
Middle East and Africa
South America
The key countries for each regions are also included such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.
For competitor segment, the report include global key players of Non-Human Primate Pre-clinical studies at Contract Market as well as some small players. The information for each competitor include:
Company Profile
Main Business Information
SWOT Analysis
Sales Volume, Revenue, Price and Gross Margin
Market Share
By Study Type
Pharmacokinetics (PK) and Pharmacodynamics (PD) Studies
Toxicology Studies
Acute Toxicology
Chronic Toxicology:
Developmental and Reproductive Toxicology (DART)
Safety Assessment Studies
Safety Pharmacology
Carcinogenicity Studies
Efficacy Studies
Immunogenicity Studies
Vaccine Development Studies
Non-Human Primate (NHP) pre-clinical studies at CROs are divided into several study types that help assess various aspects of a drug or therapy. Pharmacokinetics (PK) and Pharmacodynamics (PD) studies analyze how the drug is absorbed, distributed, metabolized, and eliminated, as well as its effects on the body. Toxicology studies evaluate the potential adverse effects, with acute toxicology focusing on short-term exposure and chronic toxicology on long-term exposure. Developmental and Reproductive Toxicology (DART) examines the effects on reproduction and fetal development. Safety assessment and safety pharmacology ensure the therapy does not cause harm to vital organs or systems. Carcinogenicity studies assess whether long-term use may lead to cancer. Efficacy studies determine if the therapy works as intended, while immunogenicity studies explore the immune response. Vaccine development studies focus on the creation and testing of vaccines, a critical step in combating infectious diseases. Each type provides essential insights for ensuring a therapy s safety and effectiveness before advancing to human trials.
By Application
Infectious Disease
Immunological Disease
Cancer
Cardiovascular Disease
Metabolic Diseases
Genetic Disease
Respiratory Diseases
Neurological Disease
Female Related Diseases
Others
Non-Human Primate (NHP) pre-clinical studies at CROs are essential across a wide range of applications, each targeting different health conditions. Infectious disease studies are crucial for developing vaccines and treatments for viral, bacterial, and parasitic infections. Immunological disease research focuses on conditions like autoimmune disorders, helping to evaluate immune-modulating therapies. Cancer studies leverage NHP models to understand tumor growth and test chemotherapy, immunotherapy, or targeted treatments. Cardiovascular disease research helps assess the effects of new therapies on heart and blood vessel health. In metabolic diseases, such as diabetes, NHPs provide insights into how treatments affect metabolism and organ function. Genetic disease studies investigate therapies for inherited disorders using models that mimic human genetic conditions. Respiratory disease research, including conditions like asthma or COPD, uses NHPs to test inhaled therapies and understand lung function. Neurological disease studies, critical for conditions like Alzheimer's or Parkinson's, leverage the similarities between primate and human nervous systems. Female-related diseases, such as endometriosis or breast cancer, use NHP models for understanding disease progression and treatment effects. Finally, other applications include various disease areas not covered by these main categories, ranging from gastrointestinal disorders to dermatological diseases.
By Species Type
Macaques
Rhesus Macaques
Baboons
Marmosets
Chimpanzees
Other Primate Species
Non-Human Primate (NHP) pre-clinical studies involve various species, each chosen for specific research based on their physiological similarities to humans. Macaques, including the Rhesus macaques, are among the most commonly used species due to their close genetic resemblance to humans. They are widely employed in research for infectious diseases, vaccines, and neuroscience due to their well-characterized immune systems and cognitive functions. Baboons are often used in cardiovascular and reproductive studies, as their large size and organ systems make them suitable models for complex diseases. Marmosets, small New World monkeys, are commonly used in neurodegenerative research, particularly for Parkinson's and Alzheimer's diseases, due to their manageable size and shorter lifespan, which allows for faster study cycles. Chimpanzees, once widely used, have seen a significant decline in use due to ethical concerns and their endangered status, although they were previously critical for hepatitis and HIV research. Other primate species, such as cynomolgus monkeys and squirrel monkeys, are also utilized for specialized studies depending on the nature of the disease or treatment being tested. Each species brings unique physiological traits to the table, allowing researchers to select the most appropriate model based on the specific requirements of the pre-clinical study.
Study Phase
Early Discovery/Screening
Pre-Clinical Development
Regulatory Pre-Clinical
In Non-Human Primate (NHP) pre-clinical studies, the process is divided into distinct phases, each with a specific goal in the drug development pipeline. Early discovery/screening is the first phase, where researchers identify potential drug candidates or therapeutic targets. This phase focuses on understanding the basic mechanisms of disease, identifying biological pathways, and conducting high-throughput screening of compounds. NHPs may be involved at this stage to provide early data on efficacy, pharmacokinetics (PK), and safety profiles in complex systems, especially for diseases where other animal models are insufficient. The pre-clinical development phase is more advanced, where promising compounds undergo extensive testing in NHP models to assess their safety and efficacy before they can be tested in humans. During this phase, studies focus on detailed toxicology, pharmacodynamics (PD), PK, and dose-response relationships. NHPs are particularly valuable in fields like immunology, infectious diseases, and neurodegenerative disorders, providing insights that are crucial for moving forward with clinical trials. Finally, the regulatory pre-clinical phase involves gathering the comprehensive data required for submission to regulatory authorities such as the FDA or EMA. This stage includes Good Laboratory Practice (GLP)-compliant toxicology studies, long-term safety assessments, and reproductive and developmental toxicology (DART) testing. These studies provide the final verification that a treatment is safe for human trials, making NHP models vital in ensuring that therapies meet stringent regulatory standards before advancing to clinical stages.
By End User
Pharmaceutical and Biotechnology Companies
Academic and Research Institutions
Government Agencies
Non-Profit Organizations
Non-Human Primate (NHP) pre-clinical studies are utilized by a variety of end users, each with distinct goals and applications. Pharmaceutical and biotechnology companies are the primary users, employing NHP models to test drug candidates and biologics for safety, efficacy, and regulatory compliance before progressing to human trials. These studies are essential for developing vaccines, gene therapies, cancer treatments, and neurological drugs, ensuring that the treatments are effective and safe for human use. NHP models are especially valuable for complex diseases where other animal models fall short, such as in immunology and infectious diseases. Academic and research institutions also rely on NHP studies for basic scientific research and translational studies. They often focus on understanding disease mechanisms, exploring new therapeutic approaches, and collaborating with pharmaceutical companies to advance new drug discoveries. These institutions contribute to the foundational knowledge that drives innovation in drug development. Government agencies like the National Institutes of Health (NIH) or the Food and Drug Administration (FDA) use NHP pre-clinical studies to evaluate the safety and efficacy of new treatments in the context of public health needs. These agencies may also research vaccines or treatments for emerging infectious diseases, such as COVID-19. Non-profit organizations often focus on specific diseases or public health challenges. They support NHP pre-clinical research to drive advancements in areas like neglected tropical diseases, rare genetic disorders, or global health concerns. Through funding and partnerships, they help bridge the gap between early discovery and clinical application, ensuring that promising therapies reach those in need. Each of these end users plays a crucial role in the continuum of drug development, utilizing NHP studies to bring innovative treatments to the market.
Key Players
ABL, Inc.
Applied BioCode Corporation
BioLegend, Inc.
Exocell, Inc.
HUREL Corporation
iQ Biosciences
Mabtech AB,
Charles River Laboratories
Laboratory Corporation of America
WuXi AppTec
Please ask for sample pages for full companies list
Base Year: 2023
Historical Data: from 2019 to 2023
Forecast Data: from 2024 to 2031
Any special requirements about this report, please let us know and we can provide custom report.
TABLE OF CONTENTS
Market Taxonomy
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis and Recommendations
1.3. RA Analysis and Recommendations
2. Market Introduction
2.1. Market Definition
3. Market Background
3.1. Parent/Associated Market Overview
3.1.1.Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Outlook
3.1.2.Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Overview
3.2. Effect of Covid-19 Impact
3.3. Macro-Economic Overview
3.3.1. GDP Growth
3.3.2. Retail Industry Growth
3.4. Pricing Analysis
3.5. Challenges related to adoption of Non-Human Primate Pre-clinical studies at Contract Research Organizations Market
3.6. Regulations of Non-Human Primate Pre-clinical studies at Contract Research Organizations Market
3.7. Forecast Factors: Relevance and Impact
3.8. Market Dynamics
3.8.1. Drivers
3.8.2. Restraints
3.8.3. Opportunity
3.8.4. Trends
3.8.5. SWOT Analysis
4. Market Forecast
4.1. Market Value Projections
4.2. Market Size Projections
4.3. Y-o-Y Projections
4.4. Absolute Opportunity Analysis
5. Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value Chain Analysis
5.1.Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value Chain
5.1.1. List of Raw Material Suppliers
5.1.2. List of Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Manufacturers
5.1.3. List of Segment
6. Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Analysis By Study Type
6.1. Introduction
6.1.1. Market Value Share Analysis By Study Type
6.1.2. Y-o-Y Growth Analysis By Study Type
6.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Study Type
6.3. Market Attractiveness Analysis Age Group
7. Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Analysis By Application
7.1. Introduction
7.1.1. Market Value Share Analysis By Application
7.1.2. Y-o-Y Growth Analysis By Application
7.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Application
7.3. Market Attractiveness Analysis By Application
8. Market Structure Analysis
8.1. Market Analysis by Tier of Companies
8.1.1. By Large, Medium, and Small
8.2. Market Concentration
8.2.1. By Top 5 and by Top 10
8.3. Type ion Capacity Share Analysis
8.3.1. By Large, Medium, and Small
8.3.2. By Top 5 and Top 10
8.4. Technology Roadmap
9. Competition Analysis
9.1. Competition Dashboard
9.2. Company Profiles (15 Companies)
9.2.1. ABL, Inc.
9.2.1.1. Overview
9.2.1.2. Type Portfolio
9.2.1.3. Financial Overview
9.2.2. Applied BioCode Corporation
9.2.2.1. Overview
9.2.2.2. Type Portfolio
9.2.2.3. Financial Overview
9.2.3. BioLegend, Inc.
9.2.3.1. Overview
9.2.3.2. Type Portfolio
9.2.3.3. Financial Overview
9.2.4. Exocell, Inc.
9.2.4.1. Overview
9.2.4.2. Type Portfolio
9.2.4.3. Financial Overview
9.2.5. HUREL Corporation
9.2.5.1. Overview
9.2.5.2. Type Portfolio
9.2.5.3. Financial Overview
9.2.6. iQ Biosciences
9.2.6.1. Overview
9.2.6.2. Type Portfolio
9.2.6.3. Financial Overview
9.2.7. Mabtech AB,
9.2.7.1. Overview
9.2.7.2. Type Portfolio
9.2.7.3. Financial Overview
9.2.8.Charles River Laboratories
9.2.8.1. Overview
9.2.8.2. Type Portfolio
9.2.8.3. Financial Overview
9.2.9. Laboratory Corporation of America
9.2.9.1. Overview
9.2.9.2. Type Portfolio
9.2.9.3. Financial Overview
9.2.10. WuXi AppTec
9.2.10.1. Overview
9.2.10.2. Type Portfolio
9.2.10.3. Financial Overview
9.2.11. COMPANY11
9.2.11.1. Overview
9.2.11.2. Type Portfolio
9.2.11.3. Financial Overview
9.2.12. COMPANY12
9.2.12.1. Overview
9.2.12.2. Type Portfolio
9.2.12.3. Financial Overview
9.2.13. COMPANY13
9.2.13.1. Overview
9.2.13.2. Type Portfolio
9.2.13.3. Financial Overview
9.2.14. COMPANY14
9.2.14.1. Overview
9.2.14.2. Type Portfolio
9.2.14.3. Financial Overview
9.2.15. COMPANY15
9.2.15.1. Overview
9.2.15.2. Type Portfolio
9.2.15.3. Financial Overview
10. Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Analysis By Region
10.1. Introduction
10.1.1. Market Value Share Analysis By Region
10.1.2. Y-o-Y Growth Analysis By Region
10.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Region
10.2.1. North America
10.2.2. Middle East and Africa
10.2.3. South America
10.2.4. Asia-Pacific
10.2.5. Others
10.3. Current Market Size (USD Mn) Forecast 2023-2030 By Region
10.3.1. North America
10.3.2. Middle East and Africa
10.3.3. South America
10.3.4. Asia-Pacific
10.3.5. Others
10.4. Market Attractiveness Analysis By Region
11. North America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Analysis
11.1. Introduction
11.2. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
11.2.1. U.S.
11.2.2. Canada
11.2.3. Mexico
11.2.4. Rest of North America
11.3. Current Market Size (USD Mn) Forecast 2023-2030 By Country
11.3.1. U.S.
11.3.2. Canada
11.3.3. Mexico
11.3.4. Rest of North America
11.4. Historical Market Size (USD Mn) Analysis 2018-2022 By Study Type
11.5. Current Market Size (USD Mn) Forecast 2023-2030 By Study Type
11.6. Historical Market Size (USD Mn) Analysis 2018-2022 By Application
11.7. Current Market Size (USD Mn) Forecast 2023-2030 By Application
12. South America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Analysis
12.1. Introduction
12.2. Regional Pricing Analysis
12.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
12.3.1. Brazil
12.3.2. Argentina
12.3.3. Rest of South America
12.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
12.4.1. Brazil
12.4.2. Argentina
12.4.3. Rest of South America
12.5. Historical Market Size (USD Mn) Analysis 2018-2022 By Study Type
12.6. Current Market Size (USD Mn) Forecast 2023-2030 By Study Type
12.7. Historical Market Size (USD Mn) Analysis 2018-2022 By Application
12.8. Current Market Size (USD Mn) Forecast 2023-2030 By Application
13. Europe Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Analysis
13.1. Introduction
13.2. Regional Pricing Analysis
13.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
13.3.1. Germany
13.3.2. Italy
13.3.3. France
13.3.4. Spain
13.3.5. U.K.
13.3.6. Rest of Europe
13.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
13.4.1. Germany
13.4.2. Italy
13.4.3. France
13.4.4. Spain
13.4.5. U.K.
13.4.6. Rest of Europe
13.5. Historical Market Size (USD Mn) Analysis 2018-2022 By Study Type
13.6. Current Market Size (USD Mn) Forecast 2023-2030 By Study Type
13.7. Historical Market Size (USD Mn) Analysis 2018-2022 By Application
13.8. Current Market Size (USD Mn) Forecast 2023-2030 By Application
14. Middle East and Africa Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Analysis
14.1. Introduction
14.2. Regional Pricing Analysis
14.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
14.3.1. Saudi Arabia
14.3.2. U.A.E.
14.3.3. South Africa
14.3.4. Turkey
14.3.5. Rest of Middle East and Africa
14.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
14.4.1. Saudi Arabia
14.4.2. U.A.E.
14.4.3. South Africa
14.4.4. Turkey
14.4.5. Rest of Middle East and Africa
15. Asia-Pacific Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Analysis
15.1. Introduction
15.2. Regional Pricing Analysis
15.3. Historical Market Size (USD Mn) Analysis 2018-2022 By Country
15.3.1. China
15.3.2. India
15.3.3. Japan
15.3.4. South Korea
15.3.5. Singapore
15.3.6. Australia and New Zealand
15.3.7. Rest of Asia-Pacific
15.4. Current Market Size (USD Mn) Forecast 2023-2030 By Country
15.4.1. China
15.4.2. India
15.4.3. Japan
15.4.4. South Korea
15.4.5. Singapore
15.4.6. Australia and New Zealand
15.4.7. Rest of Asia-Pacific
i. Research Methodology
ii. Assumptions & Acronyms
LIST OF FIGURES
Figure 01: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, BPS Analysis,By Study Type, 2018(H), 2023(E) & 2030(F)
Figure 02: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, Y-O-Y Growth,By Study Type, 2020(A) - 2030(F)
Figure 03: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Attractiveness Analysis, By Study Type (2020)
Figure 04: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, BPS Analysis, By Application, 2018(H), 2023(E) & 2030(F)
Figure 05: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, Y-O-Y Growth, By Application, 2018(H) - 2030(F)
Figure 06: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Attractiveness Analysis, By Application
Figure 07: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, Value Analysis, By Study Type, 2018(H)-2030(F)
Figure 08: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, Value Analysis, by By Application, 2018(H)-2030(F)
Figure 09: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, BPS Analysis, by Region, 2018(H), 2023(E) & 2030(F)
Figure 10: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, Y-O-Y Growth, by Region, 2018(H) - 2030(F)
Figure 11: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Attractiveness Analysis, by Region
Figure 12: North America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn Forecast, 2018 – 2022
Figure 13: North America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn Forecast, 2023 – 2030
Figure 14: South America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, 2018 – 2022
Figure 15: South America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, 2023 – 2030
Figure 16: Europe Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, 2018 – 2022
Figure 17: Europe Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, 2023 – 2030
Figure 18: Middle East and Africa Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, 2018 – 2022
LIST OF TABLES
Table 01: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Study Type, 2018(H) – 2030(F)
Table 02: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Application, 2018(H) – 2030(F)
Table 03: Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 04: North America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 05: North America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast,By Study Type, 2018(H) – 2030(F)
Table 06: North America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Application, 2018(H) – 2030(F)
Table 07: South America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 08: South America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast,By Study Type, 2018(H) – 2030(F)
Table 09: South America Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Application, 2018(H) – 2030(F)
Table 10: Europe Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) and Forecast, by Country, 2018(H) – 2030(F)
Table 11: Europe Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Study Type, 2018(H) – 2030(F)
Table 12: Europe Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Application EndUser, 2018(H) – 2030(F)
Table 13: Middle East and Africa Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Country, 2018(H) – 2030(F)
Table 14: Middle East and Africa Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Study Type, 2018(H) – 2030(F)
Table 15: Middle East and Africa Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Application, 2018(H) – 2030(F)
Table 16: Asia-Pacific Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, by Country, 2018(H) – 2030(F)
Table 17: Asia-Pacific Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Study Type, 2018(H) – 2030(F)
Table 18: Asia-Pacific Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Value (USD Mn) Forecast, By Application, 2018(H) – 2030(F)
This report can be customized according to your requirements. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
Stats And Research ™ Copyright © 2024 .